This funding will accelerate the development of Immunoscore® in selected cancers, and support set up of commercial activities in the US This round was led by PSIM fund managed by Bpifrance in the framework of the program ‘Investing...

HalioDx receives CLIA Compliance for its laboratory based in Marseille Immunoscore® Colon, is now available to US patients in selected states with a turnaround time of 10 days Marseille, June 21, 2017 - HalioDx announced today that...